Boehringer Ingelheim International Gmbh

Genentech, Inc.

Janssen Biotech, Inc.

Macrogenics, Inc.

Tanox, Inc.

Ablynx N.v.

Janssen Pharmaceutica Nv

Altrubio Inc.

Sanjaya Singh

Rajkumar Ganesan

Sek Chung Fung

Rachel Rebecca Barrett

Keith Allen Canada

Alisa K Waterman

Herren Wu

Scott Ronald Brodeur

Iqbal S Grewal

Matthew Moyle

Mason Lu

Tobias Litzenburger

Changning Yan

Dan Huang

Leslie Sydnor Johnson

Erik Depla

Kang Li

Toon Laeremans

Pankaj Gupta

Diane Van Hoorick

Bin-Bing Stephen Zhou

Qi Pan

Sathyadevi Venkataramani

Cedric Jozef Néotère Ververken

Henry Bernard Lowman

Robert F Kelley

Ling-Ling An

Haiguang Xiao

Sarah Low

Jinquan Luo

Michael Dziegelewski

Sherry La Porte

Fang Yi

Robert Copenhaver

Catherine Foster

Michael Riis Hansen

Norbert Hauel

John Lee

Yucheng Li

Adam Zwolak

Philip Nicholas Gorman

John James Miglietta

Joanne Van Ryn

Raymond Brittingham

Tao Wu

Katrina Mary Catron

Lee Edward Frego

Ernest Lee Raymond

Xiangyang Zhu

Wenjuan Wu

Daw-Tsun Shih

Ashraf Khalil

Haixia Wu

Kathleen Last-Barney

Nelamangala Nagaraja

Amy Marie Nicoletti

Patricia Giblin

David Presky

John Edward Park

Holger Rosenbrock

Remko Alexander Bakker

Vladimir H Voynov

Colleen Kane

Theresa Marie McDevitt

Fei Shen

Sebastian Bandholtz

Ulrich Kunz

Peter Michael Benz

Jun Chen

Degang Song

Rolf Herrmann

Cynthia Hess Kenny

Leo Thomas

Steven Jacobs

Sheng-Jiun Wu

Marc Mercken

Ricardo Attar

Chichi Huang

Barbara Enenkel

Christopher Ronald Sarko

Patrick Garidel

Cedric Jozef Neotere Ververken

Wilson Edwards

Nick Devoogdt

Francois Gaudet

Priyanka Gupta

Tony Lahoutte

Lore Florin

Ulrike Philippar

Yingzhe Li

Sylvie Laquerre

Philip L Cooper

Bianca Van Broeck

Fei Han

Juergen Prestle

Nina Zippel

Cassandra L Lowenstein

Triveni K Bhatt

Dirk Brehmer

Michael Dennis Feldkamp

The disclosure provides antigen binding domains that bind cluster of differentiation 3 (CD3) protein, comprising the antigen binding domains that bind CD3ε, polynucleotides encoding them, vectors, host cells, methods of making and using them.

Proteins comprising CD3 antigen binding domains and uses thereof

Provided herein, in certain aspects, are antibodies that bind to CD28, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Also provided herein, in certain aspects, are multispecific antibodies that bind to CD28, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making and using the antibodies are also provided.

Immune targeting molecules and uses thereof

The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.

Nucleic acids encoding CX3CR1-binding polypeptides comprising immunoglobulin single variable domains

Provided herein are multispecific antibodies, that bind to CD79b and CD22, polynucleotides encoding them, vectors, host cells, methods of making and using them.

Antibody targeting CD22 and CD79B

Provided herein are multispecific molecules comprising a first binding domain that specifically binds to polymeric immunoglobulin receptor (pIgR) and a second binding domain that specifically binds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and related methods for the treatment of patients infected with SARS-CoV-2.

Materials and methods for multidirectional biotransportation in virotherapeutics

Molecules, including antibodies and antigen-binding fragments thereof that specifically bind to a linker peptide, and methods of producing and using the described antibodies and antigen-binding fragments are presented herein. Also presented herein methods of generating antibodies that specifically bind to an immunorecessive epitope.

Materials and methods for enhanced linker targeting

Provided herein are multispecific antibodies, including trispecific antibodies that bind to CD79b, CD20 and CD3, and bispecific antibodies that bind to CD79b and CD3, and multispecific antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided multispecific antibodies or multispecific antigen-binding fragments, cells expressing the provided multispecific antibodies or multispecific antigen-binding fragments, as well as associated vectors and detectably labeled multispecific antibodies or multispecific antigen-binding fragments. In addition, methods of producing and using the provided multispecific antibodies and multispecific antigen-binding fragments are described. Further provided herein are isolated antibodies that bind to CD79b and antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided CD79b-specific antibodies or antigen-binding fragments, cells expressing the provided CD79b-specific antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled CD79b-specific antibodies or antigen-binding fragments. In addition, methods of producing and using the provided CD79b-specific antibodies and antigen-binding fragments are described.

Trispecific antibody targeting CD79b, CD20, and CD3

Provided herein, in certain aspects, are antibodies that bind to T cell receptor (TCR) Vγ9 (TRGV9), TCR Vδ2 (TRDV2), or the TCR gamma/delta constant region (TRGDC), as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making and using the antibodies are also provided.

Compositions and methods for modulating delta gamma chain mediated immunity

The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor, G-protein coupled receptor family C group 5 member D (GPRC5D), and immunoresponsive cells comprising such CARs, for the treatment of cancer.

GPRC5D chimeric antigen receptors and cells expressing the same

Embodiments of the present invention provide isolated proteins comprising antigen binding domains that bind kallikrein related peptidase 2 (hK2), including monospecific and bispecific antibodies. Additional embodiments of the invention provide polynucleotides encoding the hk2-specific proteins, vectors, host cells, and methods of making and using them.

Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses

The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a human Kallikrein-2 (hK2), and immunoresponsive cells comprising such CARs, for the treatment of cancer.

Anti-human kallikrein-2 (hK2) chimeric antigen receptor (CAR) and methods of use thereof

Provided here in are methods of producing induced pluripotent stem cells (iPSCs) and isolated population of produced induced pluripotent stem cells (iPSCs). Also provided herein are methods of treating a subject in need thereof using the produced iPSCs or pharmaceutical compositions comprising the produced iPSCs.

Materials and methods for the manufacture of pluripotent stem cells

Anti-Vβ17 antibodies or antigen binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases.

Methods and compositions for modulating beta chain mediated immunity

Provided herein, in certain aspects, are antibodies that bind to CD8, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Also provided herein, in certain aspects, are antibodies that bind to CD4, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Also provided herein, in certain aspects, are multispecific antibodies that bind to CD4 and CD8, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making the antibodies are also provided.

Bioengineered T cell mediated immunity, materials and other methods for modulating cluster of differentiation IV and/or VIII

Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein.

Anti-PSGL-1 antibodies and uses thereof

Growing community of inventors

Sandy Hook, CT, United States of America

Sanjaya Singh